Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001398 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Factor Medication for Aplastic Anemia
A Phase 1 study of Aplastic Anemia and Pancytopenia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00001398: Completed Phase 1 study of Aplastic Anemia and Pancytopenia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001398 is a Phase 1 study of Aplastic Anemia and Pancytopenia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 40 participants, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001398, a Phase 1 study of Aplastic Anemia and Pancytopenia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and evaluation of the effect of r-metHuSCF on peripheral blood counts. Potential effects of r-metHuSCF on frequency of need for red cell or platelet transfusions and on bone marrow morphology/cellularity will also be evaluated.
Conditions Studied
Interventions
- DRUG Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1993-10 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00001398 record still lists
NCT00001398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target.
The record links to 2 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) is the first listed.
NCT00001398 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001398 about?
NCT00001398 is a clinical study titled "Stem Cell Factor Medication for Aplastic Anemia". This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and ...
What is the current status of trial NCT00001398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1993-10. Estimated completion is 2002-06.
What conditions does trial NCT00001398 study?
This clinical trial studies the following conditions: Aplastic Anemia, Pancytopenia.
What interventions are being tested in trial NCT00001398?
The interventions under investigation include: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) (DRUG).
Who is sponsoring clinical trial NCT00001398?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001398 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001398's enrollment target sits among peer trials
40 9th of 23 higher than 14 of 23 other Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
COMPLETED · Phase 1
-
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
COMPLETED · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia